Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Surgery
Published in: World Journal of Surgery 12/2021

01-12-2021 | Kidney Transplantation | Surgical Symposium Contribution

Transplanting Organs from Donors with HIV or Hepatitis C: The Viral Frontier

Authors: Brian J. Boyarsky, Alexandra T. Strauss, Dorry L. Segev

Published in: World Journal of Surgery | Issue 12/2021

Login to get access

Abstract

A wide gap between the increasing demand for organs and the limited supply leads to immeasurable loss of life each year. The organ shortage could be attenuated by donors with human immunodeficiency virus (HIV) or hepatitis C virus (HCV). The transplantation of organs from HIV+ deceased donors into HIV+ individuals (HIV D+ /R+) was initiated in South Africa in 2010; however, this practice was forbidden in the USA until the HIV Organ Policy Equity (HOPE) Act in 2013. HIV D+/R+ transplantation is now practiced in the USA as part of ongoing research studies, helping to reduce waiting times for all patients on the waitlist. The introduction of direct acting antivirals for HCV has revolutionized the utilization of donors with HCV for HCV-uninfected (HCV−) recipients. This is particularly relevant as the HCV donor pool has increased substantially in the context of the rise in deaths related to drug overdose from injection drug use. This article serves to review the current literature on using organs from donors with HIV or HCV.
Literature
1.
Palella FJ Jr, Delaney KM, Moorman AC et al (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New Engl J Med 338:853–860PubMed
2.
Mocroft A, Brettle R, Kirk O et al (2002) Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. Aids 16:1663–1671PubMed
3.
Antiretroviral Therapy Cohort Collaboration (2010) Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 50:1387–1396
4.
Stock PG, Barin B, Murphy B et al (2010) Outcomes of kidney transplantation in HIV-infected recipients. New Engl J Med 363:2004–2014PubMed
5.
Locke JE, Mehta S, Reed RD et al (2015) A national study of outcomes among HIV-infected kidney transplant recipients. J Am Soc Nephrol 26:2222–2229PubMedPubMedCentral
6.
Locke JE, Gustafson S, Mehta S et al (2017) Survival benefit of kidney transplantation in HIV-infected patients. Ann Surg 265:604–608PubMed
7.
Locke JE, Reed RD, Mehta SG et al (2015) Center-level experience and kidney transplant outcomes in HIV-infected recipients. Am J Transpl 15:2096–2104
8.
Rodriguez RA, Mendelson M, O’Hare AM et al (2003) Determinants of survival among HIV-infected chronic dialysis patients. J Am Soc Nephrol 14:1307–1313PubMed
9.
Trullas JC, Cofan F, Barril G et al (2011) Outcome and prognostic factors in HIV-1-infected patients on dialysis in the cART era: a GESIDA/SEN cohort study. J Acquir Immune Defic Syndr 57:276–283PubMed
10.
Locke JE, Mehta S, Sawinski D et al (2017) Access to kidney transplantation among HIV-infected waitlist candidates. Clin J Am Soc Nephrol 12:467–475PubMedPubMedCentral
11.
Muller E, Kahn D, Mendelson M (2010) Renal transplantation between HIV-positive donors and recipients. New Engl J Med 362(24):2336–2337PubMed
12.
Muller E, Barday Z, Mendelson M et al (2015) HIV-positive-to-HIV-positive kidney transplantation–results at 3 to 5 years. New Engl J Med 372:613–620PubMed
13.
Boyarsky BJ, Segev DL (2016) From bench to bill: how a transplant nuance became 1 of only 57 laws passed in 2013. Ann Surg 263:430–433PubMed
14.
Durand CM, Segev D, Sugarman J (2016) Realizing HOPE: the ethics of organ transplantation from HIV-positive donors. Ann Intern Med 165:138–142PubMedPubMedCentral
15.
Boyarsky BJ, Durand CM, Palella FJ Jr et al (2015) Challenges and clinical decision-making in HIV-to-HIV transplantation: insights from the HIV literature. Am J Transpl 15:2023–2030
16.
Boyarsky BJ, Hall EC, Singer AL et al (2011) Estimating the potential pool of HIV-infected deceased organ donors in the United States. Am J Transpl 11:1209–1217
17.
Richterman A, Sawinski D, Reese PP et al (2015) An assessment of HIV-infected patients dying in care for deceased organ donation in a United States urban center. Am J Transpl 15:2105–2116
18.
Cash A, Luo X, Chow EKH et al (2018) HIV+ deceased donor referrals: a national survey of organ procurement organizations. Clin Transpl 32:e13171
19.
Werbel WA, Durand CM (2019) Solid organ transplantation in HIV-infected recipients: history, progress, and frontiers. Curr HIV/AIDS Rep 16:191–203PubMedPubMedCentral
20.
Muller E, Barday Z (2018) HIV-positive kidney donor selection for HIV-positive transplant recipients. J Am Soc Nephrol 29:1090–1095PubMedPubMedCentral
21.
22.
Durand CM, Werbel W, Doby B et al (2020) Clarifying the HOPE act landscape: the challenge of donors with false-positive HIV results. Am J Transpl 20:617–619
23.
Jain V, Liegler T, Vittinghoff E et al (2010) Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002–2009. PLoS One 5:e15510PubMedPubMedCentral
24.
25.
Selhorst P, Combrinck CE, Manning K et al (2019) Longer-term outcomes of HIV-positive-to-HIV-positive renal transplantation. New Engl J Med 381:1387–1389PubMed
26.
Bonny TS, Kirby C, Martens C et al (2020) Outcomes of donor-derived superinfection screening in HIV-positive to HIV-positive kidney and liver transplantation: a multicentre, prospective, observational study. Lancet HIV 7:e611–e619PubMedPubMedCentral
27.
Muzaale AD, Althoff KN, Sperati CJ et al (2017) Risk of end-stage renal disease in HIV-positive potential live kidney donors. Am J Transpl 17:1823–1832
28.
29.
Van Pilsum Rasmussen SE, Bowring MG, Shaffer AA et al (2018) Knowledge, attitudes, and planned practice of HIV-positive to HIV-positive transplantation in US transplant centers. Clin Transpl 32:e13365
30.
Nguyen AQ, Anjum SK, Halpern SE et al (2018) Willingness to donate organs among people living with HIV. J Acquir Immune Defic Syndr 79:e30–e36PubMedPubMedCentral
31.
Van Pilsum Rasmussen SE, Henderson ML, Bollinger J et al (2018) Perceptions, motivations, and concerns about living organ donation among people living with HIV. AIDS Care 30:1595–1599PubMedPubMedCentral
32.
33.
Sageshima J, Troppmann C, McVicar JP et al (2018) Impact of willingness to accept hepatitis C seropositive kidneys among hepatitis C RNA-positive waitlisted patients. Transplantation 102:1179–1187PubMedPubMedCentral
34.
Kucirka LM, Singer AL, Ros RL et al (2010) Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transpl 10:1238–1246
35.
Bucci JR, Lentine KL, Agodoa LY, et al (2004) Outcomes associated with recipient and donor hepatitis C serology status after kidney transplantation in the United States: Analysis of the USRDS/UNOS database. Clin Transpl 51–61
36.
Scalea JR, Barth RN, Munivenkatappa R et al (2015) Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts. Transplantation 99:1192–1196PubMed
37.
Shelton BA, Sawinski D, Mehta S et al (2018) Kidney transplantation and waitlist mortality rates among candidates registered as willing to accept a hepatitis C infected kidney. Transpl Infect Dis 20:e12829PubMed
38.
Maluf DG, Fisher RA, King AL et al (2007) Hepatitis C virus infection and kidney transplantation: predictors of patient and graft survival. Transplantation 83:853–857PubMed
39.
Carrion AF, Khaderi SA, Sussman NL (2016) Model for end-stage liver disease limbo, model for end-stage liver disease purgatory, and the dilemma of treating hepatitis C in patients awaiting liver transplantation. Liver Transpl 22:279–280PubMed
40.
Chhatwal J, Samur S, Kues B et al (2017) Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology 65:777–788PubMed
41.
Asrani SK, O’Leary JG (2015) The changing liver transplant waitlist: an emerging liver purgatory? Gastroenterology 148:493–496PubMed
42.
Durand CM, Bowring MG, Thomas AG et al (2018) the drug overdose epidemic and deceased-donor transplantation in the United States: a national registry study. Ann Intern Med 168:702–711PubMedPubMedCentral
43.
Bowring MG, Kucirka LM, Massie AB et al (2018) Changes in utilization and discard of HCV antibody-positive deceased donor kidneys in the era of direct-acting antiviral therapy. Transplantation 102:2088–2095PubMedPubMedCentral
44.
Bowring MG, Kucirka LM, Massie AB et al (2017) Changes in utilization and discard of hepatitis c-infected donor livers in the recent era. Am J Transpl 17:519–527
45.
Suryaprasad AG, White JZ, Xu F et al (2014) Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Clin Infect Dis 59:1411–1419PubMed
46.
Seth P, Scholl L, Rudd RA et al (2018) Overdose deaths involving opioids, cocaine, and psychostimulants - United States, 2015–2016. MMWR Morb Mortal Wkly Rep 67:349–358PubMedPubMedCentral
47.
Wei F, Liu J, Liu F et al (2014) Interferon-based anti-viral therapy for hepatitis C virus infection after renal transplantation: an updated meta-analysis. PLoS One 9:e90611PubMedPubMedCentral
48.
Berenguer M (2005) Treatment of hepatitis C after liver transplantation. Clin Liver Dis 9:579–600PubMed
49.
Carbognin SJ, Solomon NM, Yeo FE et al (2006) Acute renal allograft rejection following pegylated IFN-alpha treatment for chronic HCV in a repeat allograft recipient on hemodialysis: a case report. Am J Transpl 6:1746–1751
50.
Lam PW, Wachs ME, Somberg KA et al (1996) Fibrosing cholestatic hepatitis in renal transplant recipients. Transplantation 61:378–381PubMed
51.
Gasink LB, Blumberg EA, Localio AR et al (2006) Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. JAMA 296:1843–1850PubMed
52.
Pungpapong S, Aqel BA, Koning L et al (2013) Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 19:690–700PubMed
53.
Coilly A, Roche B, Dumortier J et al (2014) Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 60:78–86PubMed
54.
Gambato M, Lens S, Navasa M et al (2014) Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. J Hepatol 61:S120-131PubMed
55.
Hézode C, Fontaine H, Dorival C et al (2013) Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French early access programme (ANRS CO20-CUPIC) – NCT01514890. J Hepatol 59:434–441PubMed
56.
Kim SM, Song IH (2018) Hepatitis C virus infection in chronic kidney disease: paradigm shift in management. Korean J Intern Med 33:670–678PubMedPubMedCentral
57.
Afdhal N, Zeuzem S, Kwo P et al (2014) Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. New Engl J Med 370:1889–1898PubMed
58.
Foster GR, Afdhal N, Roberts SK et al (2015) Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. New Engl J Med 373:2608–2617PubMed
59.
Frey A, Piras-Straub K, Walker A et al (2018) The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype. Transpl Infect Dis 20:e12803
60.
Smolders EJ, Pape S, de Kanter CT et al (2017) Decreased tacrolimus plasma concentrations during HCV therapy: a drug-drug interaction or is there an alternative explanation? Int J Antimicrob Agents 49:379–382PubMed
61.
Feng HP, Caro L, Fandozzi CM et al (2018) Pharmacokinetic interactions between elbasvir/grazoprevir and immunosuppressant drugs in healthy volunteers. J Clin Pharmacol 58:666–673PubMed
62.
Ghany MG, Morgan TR (2020) Hepatitis C guidance 2019 update: american association for the study of liver diseases-infectious diseases society of america recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology 71:686–721PubMed
63.
Cotter TG, Paul S, Sandıkçı B et al (2019) Improved graft survival after liver transplantation for recipients with hepatitis C virus in the direct-acting antiviral era. Liver Transpl 25:598–609PubMed
64.
Woolley AE, Singh SK, Goldberg HJ et al (2019) Heart and lung transplants from HCV-infected donors to uninfected recipients. New Engl J Med 380:1606–1617PubMed
65.
Bowring MG, Shaffer AA, Massie AB et al (2019) Center-level trends in utilization of HCV-exposed donors for HCV-uninfected kidney and liver transplant recipients in the United States. Am J Transpl 19:2329–2341
66.
Reese PP, Abt PL, Blumberg EA et al (2018) Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: a single-group trial. Ann Intern Med 169:273–281PubMed
67.
Durand CM, Bowring MG, Brown DM et al (2018) Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial. Ann Intern Med 168:533–540PubMedPubMedCentral
68.
Molnar MZ, Nair S, Cseprekal O et al (2019) Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: single center experience. Am J Transpl 19:3046–3057
69.
Sise ME, Goldberg DS, Kort JJ et al (2020) Multicenter study to transplant hepatitis C-infected kidneys (MYTHIC): an open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C Virus infection. J Am Soc Nephrol 31:2678–2687PubMedPubMedCentral
70.
Cotter TG, Paul S, Sandıkçı B et al (2019) Increasing utilization and excellent initial outcomes following liver transplant of hepatitis C virus (HCV)-viremic donors into HCV-negative recipients: outcomes following liver transplant of HCV-viremic donors. Hepatology 69:2381–2395PubMed
71.
Thuluvath PJ, Bruno DA, Alukal J et al (2020) Use of HCV-positive livers in HCV-negative recipients. Am J Gastroenterol 115:1045–1054PubMed
72.
Potluri VS, Goldberg DS, Mohan S et al (2019) National trends in utilization and 1-year outcomes with transplantation of HCV-Viremic kidneys. J Am Soc Nephrol 30:1939–1951PubMedPubMedCentral
73.
Kwong AJ, Wall A, Melcher M et al (2019) Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors. Am J Transpl 19:1380–1387
74.
Levitsky J, Formica RN, Bloom RD et al (2017) The American society of transplantation consensus conference on the use of hepatitis C viremic donors in solid organ transplantation. Am J Transpl 17:2790–2802
75.
Bethea ED, Gaj K, Gustafson JL et al (2019) Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study. Lancet Gastroenterol Hepatol 4:771–780PubMed
76.
Chhatwal J, Samur S, Bethea ED et al (2018) Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: a modeling study. Hepatology 67:2085–2095PubMed
77.
78.
Daloul R, Pesavento T, Michaels A (2020) Expanding the use of HCV infected organs and the challenge of third-party payers. Am J Transpl 20:1463–1464
79.
Bethea ED, Samur S, Kanwal F et al (2019) Cost effectiveness of transplanting HCV-infected livers into uninfected recipients with preemptive antiviral therapy. Clin Gastroenterol Hepatol 17:739-747.e738PubMed
80.
Saxena V, Khungar V, Verna EC et al (2017) Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: results from the HCV-TARGET study. Hepatology 66:1090–1101PubMed
81.
Karkout KA, Al Sherif S, Hussein Q et al (2019) Possible acute rejection associated with the use of the new anti-hepatitis C virus medications. Avicenna J Med 9(1):32–34PubMedPubMedCentral
82.
Fernández-Ruiz M, Polanco N, García-Santiago A et al (2018) Impact of anti-HCV direct antiviral agents on graft function and immunosuppressive drug levels in kidney transplant recipients: a call to attention in the mid-term follow-up in a single-center cohort study. Transpl Int 31:887–899PubMed
83.
Chan DP, Sun HY, Wong HT et al (2016) Sexually acquired hepatitis C virus infection: a review. Int J Infect Dis 49:47–58PubMed
84.
Bari K, Luckett K, Kaiser T et al (2018) Hepatitis C transmission from seropositive, nonviremic donors to non-hepatitis C liver transplant recipients. Hepatology 67:1673–1682PubMed
85.
Theodoropoulos N, Kroll-Desrosiers A, Ison MG (2020) Utilization of deceased organ donors based on HIV, hepatitis B virus, and hepatitis C virus screening test results. Transpl Infect Dis 22:e13275PubMed
Metadata
Title
Transplanting Organs from Donors with HIV or Hepatitis C: The Viral Frontier
Authors
Brian J. Boyarsky
Alexandra T. Strauss
Dorry L. Segev
Publication date
01-12-2021
Publisher
Springer International Publishing
Published in
World Journal of Surgery / Issue 12/2021
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-020-05924-1

Other articles of this Issue 12/2021

World Journal of Surgery 12/2021 Go to the issue

Editorial Perspective

We Asked the Experts: One Size Does Not Fit All: The Option to Go Flat Following Mastectomy

Editorial Perspective

The World Journal of Surgery Announces Two New Assistant Editors for Visual Abstracts and Social Media

Surgical Symposium Contribution

Pushing the Surgical Envelope

Original Scientific Report

Immunohistochemical Inflammation in Histologically Normal Appendices in Patients with Right Iliac Fossa Pain

Original Scientific Report

Survival Benefit of Primary Tumor Resection Among Elderly Patients with Pancreatic Neuroendocrine Tumors

Surgical Symposium Contribution

Robotic Surgery: At the Crossroads of a Data Explosion